CROI 2010 Back

Die 4 wichtigsten Arbeiten zu.....
Darunavir (Prezista®)

San Francisco, 18. 2. 2010

#57 Efficacy and Safety at 48 Weeks of Once-daily vs Twice-daily DRV/r in Treatment-experienced HIV-1+ Patients with No DRV Resistance-associated Mutations: The ODIN Trial

Pedro Cahn*1, J Fourie2, B Grinsztejn3, S Hodder4, J-M Molina5, K Ruxrungtham6, C Workman7, T Van de Casteele8, P De Doncker8,and F Tomaka9

1Fndn Huesped, Buenos Aires, Argentina; 2Med Res Council, Tygerberg, South Africa; 3Inst de Pesquisa Clin Evandro Chagas-Fiocruz, Rio de Janeiro, Brazil; 4Univ of Med and Dentistry of New Jersey, Newark, US; 5Hosp St-Louis, Paris, France; 6Thai Red Cross AIDS Res Ctr, Chulalongkorn Univ, Bangkok; 7Ground Zero Med Ctr, Darlinghurst, Australia; 8Tibotec BVBA, Mechelen, Belgium; and 9Tibotec Inc, Yardley, PA, US

 

#610 Darunavir Concentrations in Seminal Plasma in Patients Receiving Darunavir/Ritonavir Monotherapy: A MONOI-ANRS136 Substudy

S Lambert-Niclot1, C Duvivier2, M Algarte-Genin3, S Pakianather3,J-L Meynard4, M-A Valantin1, J-M Molina5, A-G Marcelin1, C Katlama1, and Gilles Peytavin*6

1INSERM U943, Hosp Pitie-Salpetriere, AP-HP, Paris, France; 2Hosp Necker, Paris, France; 3INSERM U943, Paris, France; 4Hosp Saint Antoine, AP-HP, Paris, France; 5Hosp Saint Louis, AP-HP, Paris, France;and 6Hosp Bichat Claude Bernard, AP-HP, Paris, France

 

#611 Darunavir Concentrations Exceed the Protein-corrected EC50 for Wild Type HIV in the Semen of HIV-1-infected Infected Men

Stephen Taylor*1,2, A Jayasuriya1, N Dufty1, G Gilleran1, A Berry1, D Back3, E Smit1, and the Birmingham Heartlands HIV Study Group

1Birmingham Heartlands Hosp, UK; 2Univ of Birmingham, UK; and 3Univ of Liverpool, UK

 

#721 Fat Tissue Distribution Changes in HIV-infected Patients with Viral Suppression Treated with DRV/r Monotherapy vs 2 NRTI + DRV/r in the MONOI –ANRS 136 Randomized Trial: Results at 48 Weeks

Marc-Antoine Valantin*1, P Flandre2, S Kolta3, C Duvivier4, M Algarte-Genin2,D Ponscarme5, L Slama6, L Cuzin7, M Bentata8, and C Katlama1

1Hosp Pitie-Salpetriere, Paris, France; 2INSERM U943, Univ Pierre andMarie Curie, Paris, France; 3Hosp Cochin, Paris, France; 4Hosp Necker,
Paris, France; 5Hosp Saint Louis, Paris, France; 6Hosp Tenon, Paris, France; 7Hosp Purpan, Toulouse, France; and 8Hosp Avicenne, Bobigny, France


  CROI 2010Back

Meldungen

Ältere Meldungen weiter

Diese Website bietet aktuelle Informationen zu HIV/Aids sowie zur HIV/HCV-Koinfektion. Im Mittelpunkt stehen HIV-Test, Symptome und Auswirkungen der HIV-Infektion, Behandlung der HIV-Infektion, HIV-Medikamente mit Nebenwirkungen und Komplikationen, Aids, Hepatitis B und C. Ein Verzeichnis der Ärzte mit Schwerpunkt HIV ergänzt das Angebot.